Literature DB >> 12091481

The mutation of two amino acid residues in the N-terminus of tyrosine hydroxylase (TH) dramatically enhances the catalytic activity in neuroendocrine AtT-20 cells.

Akira Nakashima1, Yoko S Kaneko, Keiji Mori, Kentaro Fujiwara, Toshimitsu Tsugu, Takahiro Suzuki, Toshiharu Nagatsu, Akira Ota.   

Abstract

The sequence Arg37-Arg38 of tyrosine hydroxylase (TH) is known to play a significant role in the feedback inhibition by the end product DA. To clarify how deeply the sequence Arg37-Arg38 and the phosphorylated Ser40 of human TH type 1 (hTH1) are involved in the regulation of this feedback inhibition in mammalian cells, we generated the following mutants: (i) RR-GG, Arg37-Arg38 replaced by Gly37-Gly38; (ii) RR-EE, Arg37-Arg38 replaced by Glu37-Glu38; (iii) S40D, Ser40 replaced by Asp40; and (iv) S40A, Ser40 replaced by Ala40. In a cell-free system, the level of the DA inhibition of the RR-EE mutant enzyme was to the same or smaller degree than that of the phosphorylation-mimicking S40D. Next, AtT-20 neuroendocrine cells were transfected with wild-type and mutated TH genes because these cells were earlier shown to be capable of fully converting L-3,4-dihydroxyphenylalanine into DA, whereby the catalytic activity of TH would be expected to be inhibited by the end product DA accumulating in the cells. The level of DA accumulation in AtT-20 cells expressing the TH gene was in the order: RR-EE > S40D > S40A = RR-GG > wild-type, which was in accordance with the observations for the cell-free system. These results suggest that the sequence Arg37-Arg38 of hTH1 is a more potent determinant of the efficient production of DA in mammalian cells than is the phosphorylated Ser40-hTH1.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12091481     DOI: 10.1046/j.1471-4159.2002.00921.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  9 in total

Review 1.  The usual suspects, dopamine and alpha-synuclein, conspire to cause neurodegeneration.

Authors:  Danielle E Mor; Malcolm J Daniels; Harry Ischiropoulos
Journal:  Mov Disord       Date:  2019-01-11       Impact factor: 10.338

Review 2.  Complex molecular regulation of tyrosine hydroxylase.

Authors:  Izel Tekin; Robert Roskoski; Nurgul Carkaci-Salli; Kent E Vrana
Journal:  J Neural Transm (Vienna)       Date:  2014-05-28       Impact factor: 3.575

3.  A tango for two: Dopamine and α-synuclein synergy may explain nigrostriatal degeneration in Parkinson's disease.

Authors:  Vivian Chen; Sara Saez-Atienzar
Journal:  Mov Disord       Date:  2018-01-22       Impact factor: 10.338

4.  De novo production of the key branch point benzylisoquinoline alkaloid reticuline in yeast.

Authors:  Isis J Trenchard; Michael S Siddiqui; Kate Thodey; Christina D Smolke
Journal:  Metab Eng       Date:  2015-07-10       Impact factor: 9.783

Review 5.  Role of N-terminus of tyrosine hydroxylase in the biosynthesis of catecholamines.

Authors:  A Nakashima; N Hayashi; Y S Kaneko; K Mori; E L Sabban; Toshiharu Nagatsu; A Ota
Journal:  J Neural Transm (Vienna)       Date:  2009-04-25       Impact factor: 3.575

6.  Dopamine induces soluble α-synuclein oligomers and nigrostriatal degeneration.

Authors:  Danielle E Mor; Elpida Tsika; Joseph R Mazzulli; Neal S Gould; Hanna Kim; Malcolm J Daniels; Shachee Doshi; Preetika Gupta; Jennifer L Grossman; Victor X Tan; Robert G Kalb; Kim A Caldwell; Guy A Caldwell; John H Wolfe; Harry Ischiropoulos
Journal:  Nat Neurosci       Date:  2017-09-18       Impact factor: 24.884

Review 7.  Can Interactions Between α-Synuclein, Dopamine and Calcium Explain Selective Neurodegeneration in Parkinson's Disease?

Authors:  Michael R Post; Ori J Lieberman; Eugene V Mosharov
Journal:  Front Neurosci       Date:  2018-03-14       Impact factor: 4.677

8.  Complexity of dopamine metabolism.

Authors:  Johannes Meiser; Daniel Weindl; Karsten Hiller
Journal:  Cell Commun Signal       Date:  2013-05-17       Impact factor: 5.712

9.  The Convergence of Dopamine and α-Synuclein: Implications for Parkinson's Disease.

Authors:  Danielle E Mor; Harry Ischiropoulos
Journal:  J Exp Neurosci       Date:  2018-03-08
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.